Download PDF
Thromb Haemost 2024; 124(01): 032-039
DOI: 10.1055/a-2142-0262
Coagulation and Fibrinolysis

Clinical Implications of Discrepancy between One-Stage Clotting and Chromogenic Factor IX Activity in Hemophilia B

David E. Schmidt
1   Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden
2   Paediatric Coagulation, Astrid Lindgren Children’s Hospital, Karolinska University Hospital, Stockholm, Sweden
,
Åsa Truedsson
3   Clinical Chemistry, Karolinska University Hospital, Stockholm, Sweden
,
Annelie Strålfors
3   Clinical Chemistry, Karolinska University Hospital, Stockholm, Sweden
4   Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
,
Johanne Andersen Hojbjerg
5   Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark
6   Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
,
Nida Soutari
3   Clinical Chemistry, Karolinska University Hospital, Stockholm, Sweden
4   Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
,
Margareta Holmström
7   Coagulation Unit, Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
8   Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden
,
Susanna Ranta
1   Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden
2   Paediatric Coagulation, Astrid Lindgren Children’s Hospital, Karolinska University Hospital, Stockholm, Sweden
,
Anna Letelier
9   Department of Clinical Sciences, Lund University, Lund, Sweden
,
Annette Bowyer
10   Department of Coagulation, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
,
Rolf Ljung
9   Department of Clinical Sciences, Lund University, Lund, Sweden
,
Jovan Antovic
3   Clinical Chemistry, Karolinska University Hospital, Stockholm, Sweden
4   Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
,
Maria Bruzelius
4   Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
7   Coagulation Unit, Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
› Author Affiliations Funding D.E.S. was supported by a scholarship from the Studienstiftung des Deutschen Volkes.
› Further Information
    Permissions and Reprints


Abstract

Background Discrepancy in factor IX activity (FIX:C) between one-stage assay (OSA) and chromogenic substrate assay (CSA) in patients with hemophilia B (PwHB) introduces challenges for clinical management.

Aim To study the differences in FIX:C using OSA and CSA in moderate and mild hemophilia B (HB), their impact on classification of severity, and correlation with genotype.

Methods Single-center study including 21 genotyped and clinically characterized PwHB. FIX:C by OSA was measured using ActinFSL (Siemens) and CSA by Biophen (Hyphen). In addition, in vitro experiments with wild-type FIX were performed. Reproducibility of CSA was assessed between three European coagulation laboratories.

Results FIX:C by CSA was consistently lower than by OSA, with 10/17 PwHB having a more severe hemophilia type by CSA. OSA displayed a more accurate description of the clinical bleeding severity, compared with CSA. A twofold difference between OSA:CSA FIX:C was present in 12/17 PwHB; all patients had genetic missense variants in the FIX serine protease domain. Discrepancy was also observed with diluted normal plasma, most significant for values below 0.10 IU/mL. Assessment of samples with low FIX:C showed excellent reproducibility of the CSA results between the laboratories.

Conclusion FIX:C was consistently higher by OSA compared with the CSA. Assessing FIX:C by CSA alone would have led to diagnosis of a more severe hemophilia type in a significant proportion of patients. Our study suggests using both OSA and CSA FIX:C together with genotyping to classify HB severity and provide essential information for clinical management.

Keywords

hemophilia B - factor IX - diagnostics - assays - genotype

Authors' Contribution

D.E.S. analyzed data and wrote the manuscript. Å.T., A.S., and N.S. performed experiments. J.A.H., A.L., and R.L. contributed data and discussed the findings. A.B., J.A., S.R., and M.H. contributed data and discussed the findings. M.B. designed and supervised the study.


Note

This study was performed in the Special Coagulation Laboratory L7:04, Clinical Chemistry, Karolinska University Hospital, SE-171 76 Stockholm, Sweden.


Supplementary Material



Publication History

Received: 21 March 2023

Accepted: 25 July 2023

Accepted Manuscript online:
26 July 2023

Article published online:
18 September 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Dolan G, Benson G, Duffy A. et al. Haemophilia B: where are we now and what does the future hold?. Blood Rev 2018; 32 (01) 52-60
    CrossrefPubMedGoogle Scholar
  • 2 Tjärnlund-Wolf A, Lassila R. Phenotypic characterization of haemophilia B - understanding the underlying biology of coagulation factor IX. Haemophilia 2019; 25 (04) 567-574
    CrossrefPubMedGoogle Scholar
  • 3 Pouplard C, Trossaert M, LE Querrec A, Delahousse B, Giraudeau B, Gruel Y. Influence of source of phospholipids for APTT-based factor IX assays and potential consequences for the diagnosis of mild haemophilia B. Haemophilia 2009; 15 (01) 365-368
    CrossrefPubMedGoogle Scholar
  • 4 Peyvandi F, Oldenburg J, Friedman KD. A critical appraisal of one-stage and chromogenic assays of factor VIII activity. J Thromb Haemost 2016; 14 (02) 248-261
    CrossrefPubMedGoogle Scholar
  • 5 Strålfors A, Mikovic D, Schmidt D. et al. Genetics and hemostatic potential in persons with mild to moderate hemophilia a with a discrepancy between one-stage and chromogenic FVIII assays. Thromb Haemost 2021; 121 (01) 27-35
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Potgieter JJ, Damgaard M, Hillarp A. One-stage vs. chromogenic assays in haemophilia A. Eur J Haematol 2015; 94 (Suppl. 77) 38-44
    CrossrefPubMedGoogle Scholar
  • 7 Bowyer AE, Goodeve A, Liesner R, Mumford AD, Kitchen S, Makris M. p.Tyr365Cys change in factor VIII: haemophilia A, but not as we know it. Br J Haematol 2011; 154 (05) 618-625
    CrossrefPubMedGoogle Scholar
  • 8 Bowyer AE, Duncan EM, Antovic JP. Role of chromogenic assays in haemophilia A and B diagnosis. Haemophilia 2018; 24 (04) 578-583
    CrossrefPubMedGoogle Scholar
  • 9 Pavlova A, Delev D, Pezeshkpoor B, Müller J, Oldenburg J. Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays. Thromb Haemost 2014; 111 (05) 851-861
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Trossaert M, Lienhart A, Nougier C. et al. Diagnosis and management challenges in patients with mild haemophilia A and discrepant FVIII measurements. Haemophilia 2014; 20 (04) 550-558
    CrossrefPubMedGoogle Scholar
  • 11 Kershaw GW, Dissanayake K, Chen VM, Khoo TL. Evaluation of chromogenic factor IX assays by automated protocols. Haemophilia 2018; 24 (03) 492-501
    CrossrefPubMedGoogle Scholar
  • 12 Kihlberg K, Strandberg K, Rosén S, Ljung R, Astermark J. Discrepancies between the one-stage clotting assay and the chromogenic assay in haemophilia B. Haemophilia 2017; 23 (04) 620-627
    CrossrefPubMedGoogle Scholar
  • 13 Mårtensson A, Letelier A, Halldén C, Ljung R. Mutation analysis of Swedish haemophilia B families - high frequency of unique mutations. Haemophilia 2016; 22 (03) 440-445
    CrossrefPubMedGoogle Scholar
  • 14 Schmidt DE, Chaireti R, Bruzelius M, Holmström M, Antovic J, Ågren A. Correlation of thromboelastography and thrombin generation assays in warfarin-treated patients. Thromb Res 2019; 178: 34-40
    CrossrefPubMedGoogle Scholar
  • 15 Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1 (8476): 307-310
    Google Scholar
  • 16 Ljung R, Petrini P, Tengborn L, Sjörin E. Haemophilia B mutations in Sweden: a population-based study of mutational heterogeneity. Br J Haematol 2001; 113 (01) 81-86
    CrossrefPubMedGoogle Scholar
  • 17 Foley JH, Shehu E, Riddell A. et al. Differences in wild type- and R338L-tenase complex formation are at the root of R338L-factor IX assay discrepancies. Blood Adv 2023; 7 (03) 458-467
    CrossrefPubMedGoogle Scholar
  • 18 Rallapalli PM, Kemball-Cook G, Tuddenham EG, Gomez K, Perkins SJ. An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B. J Thromb Haemost 2013; 11 (07) 1329-1340
    CrossrefPubMedGoogle Scholar
  • 19 Xu Z, Spencer HJ, Harris VA, Perkins SJ. An updated interactive database for 1692 genetic variants in coagulation factor IX provides detailed insights into hemophilia B. J Thromb Haemost 2023; 21 (05) 1164-1176
    CrossrefPubMedGoogle Scholar
  • 20 Labarque V, Mancuso ME, Kartal-Kaess M, Ljung R, Mikkelsen TS, Andersson NG. F8/F9 variants in the population-based PedNet Registry cohort compared with locus-specific genetic databases of the European Association for Haemophilia and Allied Disorders and the Centers for Disease Control and Prevention Hemophilia A or Hemophilia B Mutation Project. Res Pract Thromb Haemost 2023; 7 (01) 100036
    CrossrefPubMedGoogle Scholar
  • 21 Li T, Miller CH, Payne AB, Craig Hooper W. The CDC hemophilia B mutation project mutation list: a new online resource. Mol Genet Genomic Med 2013; 1 (04) 238-245
    CrossrefPubMedGoogle Scholar
  • 22 Lopes TJS, Rios R, Nogueira T, Mello RF. Prediction of hemophilia A severity using a small-input machine-learning framework. NPJ Syst Biol Appl 2021; 7 (01) 22
    CrossrefPubMedGoogle Scholar
  • 23 Meireles MR, Bragatte MAS, Bandinelli E, Salzano FM, Vieira GF. A new in silico approach to investigate molecular aspects of factor IX missense causative mutations and their impact on the hemophilia B severity. Hum Mutat 2019; 40 (06) 706-715
    CrossrefPubMedGoogle Scholar